about
INterpreting the Processes of the UMPIRE Trial (INPUT): protocol for a qualitative process evaluation study of a fixed-dose combination (FDC) strategy to improve adherence to cardiovascular medications.Implementing Kanyini GAP, a pragmatic randomised controlled trial in Australia: findings from a qualitative studyUnderstanding Patient Preferences in Medication Nonadherence: A Review of Stated Preference Data.Using administrative data to look at changes in the level and distribution of out-of-pocket medical expenditure: An example using Medicare data from Australia.Healthcare expenditure on Indigenous and non-Indigenous Australians at high risk of cardiovascular diseaseUnderstanding rational non-adherence to medications. A discrete choice experiment in a community sample in AustraliaThe household economic burden of eating disorders and adherence to treatment in Australia.Patient preferences for adherence to treatment for osteoarthritis: the MEdication Decisions in Osteoarthritis Study (MEDOS).What determines adherence to treatment in cardiovascular disease prevention? Protocol for a mixed methods preference studyExamining the use of process evaluations of randomised controlled trials of complex interventions addressing chronic disease in primary health care-a systematic review protocol.An integrated general practice and pharmacy-based intervention to promote the use of appropriate preventive medications among individuals at high cardiovascular disease risk: protocol for a cluster randomized controlled trialStrategies to improve adherence to medications for cardiovascular diseases in socioeconomically disadvantaged populations: a systematic review.Mobile Telephone Text Messaging for Medication Adherence in Chronic Disease: A Meta-analysis.Interventions to improve medication adherence in coronary disease patients: A systematic review and meta-analysis of randomised controlled trials.Patient Perceptions of Treatment Delivery Platforms for Cognitive Behavioral Therapy for Insomnia.Patients' and providers' perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial.Understanding if, how and why non-adherent decisions are made in an Australian community sample: a key to sustaining medication adherence in chronic disease?Mapping the illness trajectories of insomnia: a biographical disruption?Facilitators and barriers to implementation of a pragmatic clinical trial in Aboriginal health services.Patient preferences for a polypill for the prevention of cardiovascular diseases.An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial.Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trail protocolUsing Discrete Choice Experiment to elicit patient preferences for osteoporosis drug treatments: where to from here?To Drug or Not to Drug: A Qualitative Study of Patients' Decision-Making Processes for Managing Insomnia.Investigation of attributes which guide choice in cataract surgery services in urban Sydney, Australia.Creating a new investment pool for innovative health systems research.Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.A priority-setting framework is needed to understand the value of investing in a universal drug plan.Does a Patient-Directed Financial Incentive Affect Patient Choices About Controller Medicines for Asthma? A Discrete Choice Experiment and Financial Impact AnalysisProcess evaluation of a randomised controlled trial of a pharmacological strategy to improve hypertension control: protocol for a qualitative studyMaking guidelines for economic evaluations relevant to public health in AustraliaFinancing options to sustain Medicare: are we committed to universalism?Co-payments for health care: what is their real cost?Evaluating the costs and benefits of using combination therapiesCommunity pharmacist workflow: Space for Pharmacy-based Interventions and Consultation TimE study protocol
P50
Q30540078-CDA57AE6-58F3-4A78-A36C-47DDCF3D8C0EQ30665354-0C095F52-C235-41EC-89DF-2E54957A698EQ30870323-434B75CD-AE7F-4B05-A4EA-9AF5B9A88ED8Q31166131-1D56269A-E2AD-4403-ABFC-8440FD2F92DEQ33827315-A23B17BB-2404-4890-A4B2-91223D3F77BAQ34310563-ACD6D5A4-050F-4650-BB8E-A8BC65BD5583Q34676463-F5D8ED7C-C270-4155-8722-5176B791CACFQ34707575-13E3207E-DA4C-4749-8462-69EAA4A9D642Q35536172-D0BF72AA-FC14-4084-934B-2B75F479E367Q37178693-E518260F-3F21-4F8B-BFA2-B69A689A97A9Q37278617-6C02C475-6EE0-40D6-B397-DC291B29B04EQ38082107-6B39D6FD-31BB-48B4-B62D-EF9B3BE47675Q38718502-2DEBD2EB-5F25-45A8-A50A-3CAF17CF2DE7Q38774887-9EC8D702-04A9-4E37-A496-2F86AA848E2DQ38890627-CA8BA832-8C45-497C-A1A9-2D3EAD5E8ACCQ39010505-C56E3E20-A75D-4651-8FC1-E29471CE5F54Q40213259-C5E44649-4407-49BF-97DE-F80D7A7947BCQ40436197-B4A4B696-B55A-48E1-A612-5C478DD7B4FEQ40781418-126DB1D5-0D10-4E8B-B5B6-7C4141E72847Q41438010-A5B24453-F5F2-4456-B3F3-1917546782C4Q41704756-10DCC8AE-E542-4A03-BB07-A89290D51302Q42650070-4F58A3B0-6024-4A1E-8155-564F167CDED4Q42699853-BEE336A9-662E-480D-BB57-49B2C5C1429EQ47856159-FD8B25CE-C92C-4979-9569-298FE26E2C1BQ48221327-A064A14A-2A12-414E-8903-C2930C64F9A4Q51773129-53193E32-FC9D-4A53-B1CC-8CB2C1889547Q52603946-D7D14559-8C9A-41F0-BBB6-F4F8F80C9C57Q54401986-C0019CF9-D922-46A1-AD71-3886FE3A7851Q58111990-4447CB9C-C2C4-4C5C-A93C-24416CD2B59BQ58185146-2F4515BD-678D-4DF6-BA2A-72D3DE17129DQ58185198-14993855-2152-4B20-AAD3-55F89F8D72BCQ58185207-EA7ED0E7-8476-4272-87BE-AAA2F039E61EQ58185215-1F12F8E5-B2EC-465D-8461-30B2203A61C2Q58185225-2F09D3D4-2DA5-4A5F-988F-178733E23E04Q94456001-0B5FBE1D-97C7-4B9D-B00C-47F781E1AFC0
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Tracey-Lea Laba
@ast
Tracey-Lea Laba
@en
Tracey-Lea Laba
@es
Tracey-Lea Laba
@nl
Tracey-Lea Laba
@sl
type
label
Tracey-Lea Laba
@ast
Tracey-Lea Laba
@en
Tracey-Lea Laba
@es
Tracey-Lea Laba
@nl
Tracey-Lea Laba
@sl
prefLabel
Tracey-Lea Laba
@ast
Tracey-Lea Laba
@en
Tracey-Lea Laba
@es
Tracey-Lea Laba
@nl
Tracey-Lea Laba
@sl
P106
P1153
54393310500
P31
P496
0000-0002-5182-9092